Month: February 2023

Predictive Oncology launches ACE program to partner with academic and research institutions to advance their drug discovery initiatives

Staff February 21, 2023

First round of applications due March 31, 2023EAGAN, Minn., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) today...

eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID

Staff February 21, 2023

Results presented at 30th Conference on Retroviruses and Opportunistic Infections (CROI)SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Feb. 21, 2023...

Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Staff February 21, 2023

WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology...

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 1, 2023

Staff February 21, 2023

BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...

Mersana Therapeutics to Host Fourth Quarter and Year End 2022 Conference Call on February 28, 2023

Staff February 21, 2023

CAMBRIDGE, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering...

Nautilus Biotechnology to Participate in the 43rd Annual Cowen Health Care Conference

Staff February 21, 2023

SEATTLE, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein...

IntelGenx Receives USPTO Notice of Allowance for Loxapine Orange Book Eligible Patent

Staff February 21, 2023

SAINT LAURENT, Quebec, Feb. 21, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx”), a leader in pharmaceutical...

Esperas Pharma, Inc. Announces Investment from TVM Life Science Innovation I and The Fonds de solidarité FTQ

Staff February 21, 2023

MONTRÉAL, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Esperas Pharma, Inc. (“Esperas”), a company based in Montréal, Québec, today announced a...

Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents

Staff February 21, 2023

Seborrheic dermatitis is an inflammatory skin disease affecting more than 10 million individuals in the United StatesIf approved, roflumilast foam...

Akari Therapeutics Announces Presentation of a Case Study from Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA as a Late-Breaker at The Transplantation & Cellular Therapy Tandem Meetings

Staff February 21, 2023

NEW YORK and LONDON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing...

89bio to Present Additional Pegozafermin Data in Severe Hypertriglyceridemia from Phase 2 ENTRIGUE Study at American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology

Staff February 21, 2023

SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development...

Olon and The Chemistry Department of Politecnico University Launch a Research Project on Polymorphism and Characterization of API Solid State

Staff February 20, 2023

Olon and The Chemistry Department of Politecnico University Launch a Research Project on Polymorphism and Characterization of API Solid State...

New Analyses of Sotagliflozin to Be Presented at the American College of Cardiology’s 72nd Annual Scientific Session Together With World Heart Federation’s World Congress of Cardiology

Staff February 20, 2023

Featured presentation on the time to clinical benefit of sotagliflozin in people with worsening heart failureTHE WOODLANDS, Texas, Feb. 20,...

Mineralys Therapeutics Abstracts Selected to be Presented at the American College of Cardiology Annual Scientific Session & Expo Together with the World Congress of Cardiology (ACC.23/WCC) in March 2023

Staff February 20, 2023

RADNOR, Pa., Feb. 20, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing...

Dr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023

Staff February 20, 2023

Dr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023 Dr Mathias brings a wealth of...

GN Store Nord A/S – Notice to convene the Annual General Meeting 2023

Staff February 20, 2023

GN Store Nord’s Annual General Meeting will be held on Wednesday, March 15, 2023, at 10:00 a.m. CET at the...

Novartis announces the appointment of the Chairman-Designate of Sandoz Board of Directors

Staff February 20, 2023

Gilbert Ghostine, CEO of the Swiss multi-national fragrances business Firmenich appointed Chairman-Designate of the future Sandoz BoardMr Ghostine to begin...

FDA Accepts Valneva’s Chikungunya Vaccine License Application for Priority Review

Staff February 20, 2023

Saint-Herblain (France), February 20, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that...

Sorrento Posts Form 8937 to Supplement its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”)

Staff February 19, 2023

SAN DIEGO, Feb. 18, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted an IRS Form 8937...

G Medical Innovations Holdings Ltd Announces Nasdaq Staff Listing Determination; Plans to Request Hearing

Staff February 18, 2023

Rehovot, Israel, Feb. 17, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the “Company”) announced today that...

Month: February 2023

Predictive Oncology launches ACE program to partner with academic and research institutions to advance their drug discovery initiatives

eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID

Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 1, 2023

Mersana Therapeutics to Host Fourth Quarter and Year End 2022 Conference Call on February 28, 2023

Nautilus Biotechnology to Participate in the 43rd Annual Cowen Health Care Conference

IntelGenx Receives USPTO Notice of Allowance for Loxapine Orange Book Eligible Patent

Esperas Pharma, Inc. Announces Investment from TVM Life Science Innovation I and The Fonds de solidarité FTQ

Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents

Akari Therapeutics Announces Presentation of a Case Study from Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA as a Late-Breaker at The Transplantation & Cellular Therapy Tandem Meetings

89bio to Present Additional Pegozafermin Data in Severe Hypertriglyceridemia from Phase 2 ENTRIGUE Study at American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology

Olon and The Chemistry Department of Politecnico University Launch a Research Project on Polymorphism and Characterization of API Solid State

New Analyses of Sotagliflozin to Be Presented at the American College of Cardiology’s 72nd Annual Scientific Session Together With World Heart Federation’s World Congress of Cardiology

Mineralys Therapeutics Abstracts Selected to be Presented at the American College of Cardiology Annual Scientific Session & Expo Together with the World Congress of Cardiology (ACC.23/WCC) in March 2023

Dr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023

GN Store Nord A/S – Notice to convene the Annual General Meeting 2023

Novartis announces the appointment of the Chairman-Designate of Sandoz Board of Directors

FDA Accepts Valneva’s Chikungunya Vaccine License Application for Priority Review

Sorrento Posts Form 8937 to Supplement its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”)

G Medical Innovations Holdings Ltd Announces Nasdaq Staff Listing Determination; Plans to Request Hearing

GE HealthCare drives innovation in theranostics with latest technological advances

ICPO Foundation co-founded the RLT Angels Association with the aim of growing access to Radiotheranostics to one million patients

Saudi Arabia Concludes Landmark BIO 2025 Debut as Kingdom Opens Doors to Global Biotech Collaboration

Enzon and Viskase Enter into Merger Agreement

Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA

You may have missed